[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sinonasal-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sinonasal-carcinoma":165},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,72,98,121,141],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100642073",false,"NCT07652489","Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma: A Prospective Observational Study","SPORT-SNACC: A Prospective, Multicenter, Observational Cohort Study of Surgery Plus Postoperative Radiotherapy in T4 Sinonasal Adenoid Cystic Carcinoma","SPORT-SNACC","Inclusion Criteria:\n\n1. Age 18 80 years, any gender; ECOG performance status 0 2; life expectancy ≥6 months.\n2. Histologically confirmed primary sinonasal adenoid cystic carcinoma (cribriform, tubular, solid, or mixed type). Other malignancies excluded.\n3. T4 stage (T4a or T4b) according to AJCC 8th edition, based on contrast enhanced MRI\u002FCT.\n4. N0 2 (operable lymph node metastasis allowed).\n5. M0 (no distant metastasis on chest CT and abdominal ultrasound) OR M1 with stable limited lung metastases; (c) stable on two CT scans ≥3 months apart; (d) no respiratory symptoms.\n6. Previously untreated (no radiotherapy, chemotherapy, targeted therapy, immunotherapy, or tumor resection). MDT deems technically resectable (R0\u002FR1 achievable, not diffusely unresectable).\n7. Adequate organ function within 14 days before enrollment: ANC ≥1.5×10⁹\u002FL, platelets ≥100×10⁹\u002FL, Hb ≥90 g\u002FL; ALT\u002FAST ≤2.5×ULN, TBil ≤1.5×ULN, Cr ≤1.5×ULN or CrCl ≥50 mL\u002Fmin; LVEF ≥50%, no uncontrolled arrhythmia.\n8. Willing and able to provide written informed consent for clinical data collection (and optional biospecimen banking). Investigator judges good compliance.\n\nExclusion Criteria:\n\n1. Progressive lung metastases within 6 months (new lesions or \\>20% increase); extrapulmonary metastases (liver, bone, brain); symptomatic lung metastases.\n2. MDT judged unresectable, e.g., bilateral cavernous sinus invasion, brain parenchyma invasion, bilateral internal carotid artery encasement.\n3. Primary tumor outside sinonasal cavity (e.g., major salivary glands, oropharynx); non ACC histology.\n4. Other active malignancy within 5 years (except cured basal cell carcinoma, cervical carcinoma in situ, etc.).\n5. Severe comorbidities: NYHA class III\u002FIV heart failure, recent myocardial infarction or unstable angina, uncontrolled hypertension (≥160\u002F100 mmHg); COPD requiring home oxygen or interstitial lung disease; decompensated cirrhosis; active hepatitis B\u002FC without antiviral therapy; nephropathy requiring dialysis; active serious infection; active bleeding or coagulopathy (INR \\>1.5×ULN without anticoagulation, or platelets \\\u003C50×10⁹\u002FL).\n6. Special populations: pregnant or breastfeeding; unwilling to use contraception (if childbearing potential); severe allergy to medications required for surgery\u002Fradiotherapy; severe psychiatric or cognitive disorder impairing cooperation; currently participating in another interventional trial.\n7. Unable to undergo contrast enhanced MRI (metal implants, claustrophobia, gadolinium allergy); investigator judges inability to complete follow up (e.g., living abroad, substance abuse).","ALL","18 Years","80 Years",{"count":20,"type":21},70,"ESTIMATED","OBSERVATIONAL","This observational study follows patients with T4 stage sinonasal adenoid cystic carcinoma (a rare cancer of the nasal cavity\u002Fsinuses) who receive standard treatment: surgery followed by postoperative radiotherapy. The main goal is to measure the 3-year progression-free survival rate (the percentage of patients alive without cancer growth or spread). We will also assess overall survival, recurrence, side effects, and quality of life. This multicenter, prospective study will provide much-needed real-world data to improve patient counseling and guide future research.",[25,26],"Adenoid Cystic Carcinoma","Sinonasal Carcinoma",[28],"Carcinoma, Adenoid Cystic, Sinonasal, Radiotherapy, Adjuvant, Prospective Studies, Observational Study, Progression-Free Survival","RECRUITING","2026-06-12",{"date":32,"type":33},"2026-06-17","ACTUAL",{"date":35,"type":21},"2026-06-01",{"date":37,"type":21},"2031-06-01",{"name":39,"class":40},"Eye & ENT Hospital of Fudan University","OTHER",{"id":42,"slug":4,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100636238","NCT07563088","SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma","Postoperative Adjuvant Radiotherapy Strategy for Resectable Sinonasal Adenoid Cystic Carcinoma: A Prospective, Multicenter, Real-World Study","SPARE-1st","Inclusion Criteria:\n\n* Age ≥18 years and ≤75 years.\n* Histologically confirmed adenoid cystic carcinoma of cribriform or tubular type (solid type excluded) by central pathology review.\n* Completed radical surgical resection with postoperative pathology confirming R0 resection (negative microscopic margins).\n* Tumor stage T1, T2, or T3 according to AJCC 8th edition, with N0 and M0 status.\n* Tumor originating from the nasal cavity or paranasal sinuses (excluding primary salivary gland tumors metastatic to this region).\n* ECOG performance status 0 or 1.\n* Adequate bone marrow, liver, and kidney function within 14 days before enrollment:\n\n  * Absolute neutrophil count ≥1.5 × 10⁹\u002FL, platelet count ≥100 × 10⁹\u002FL, hemoglobin ≥90 g\u002FL.\n  * Total bilirubin ≤1.5 × upper limit of normal (ULN); AST and ALT ≤2.5 × ULN.\n  * Serum creatinine ≤1.5 × ULN or calculated creatinine clearance ≥60 mL\u002Fmin (Cockcroft-Gault formula).\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Tumor stage T4, or presence of regional lymph node metastasis (N+), or distant metastasis (M1).\n* Postoperative pathology showing positive margins (R1 or R2).\n* Prior head and neck radiotherapy.\n* Concurrent active malignancy other than adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix.\n* Uncontrolled serious concomitant disease (e.g., unstable angina, recent myocardial infarction, uncontrolled hypertension).\n* Pregnant or breastfeeding women, or women of childbearing age not using effective contraception.\n* Psychological, social, or geographic factors that may interfere with study compliance.","75 Years",{"count":50,"type":21},200,"Background:\n\nSinonasal adenoid cystic carcinoma (ACC) is a rare type of cancer that starts in the nasal cavity or sinuses. Although surgery can remove the tumor, doctors often recommend radiation therapy after surgery to reduce the chance of the cancer coming back. However, radiation can cause long-term side effects such as bone damage, dry mouth, or difficulty opening the mouth. For patients whose tumor has been completely removed (called R0 resection) and who have early-stage disease (T1-T3) without spread to lymph nodes or other organs, it is not clear whether routine radiation therapy is always needed.\n\nStudy Objective:\n\nThis study aims to find out whether simply watching and waiting (surgery alone) is not worse than adding radiation therapy (surgery plus radiation) in terms of keeping patients free from cancer for at least 3 years. If surgery alone is shown to be as good as surgery plus radiation, some patients may be able to avoid the side effects of radiation.\n\nStudy Design:\n\nThis is a prospective, multicenter, real-world study. It is not a randomized trial - patients and their doctors will decide together whether to have radiation after surgery. We will follow about 200 patients from many hospitals across China. About half will receive surgery alone, and the other half will receive surgery followed by radiation therapy. All patients will be followed for at least 3 years.\n\nHypothesis:\n\nWe hypothesize that surgery alone is not inferior to surgery plus radiation therapy for 3-year disease-free survival, with a non-inferiority margin of a hazard ratio of 1.35. In other words, even if surgery alone has a slightly higher risk of cancer returning, the difference is small enough that avoiding radiation side effects may still be worthwhile.\n\nMain Outcome:\n\nThe main outcome is the percentage of patients who are alive and free from cancer recurrence (local, regional, or distant) or death from any cause at 3 years after treatment.\n\nPotential Impact:\n\nIf our hypothesis is confirmed, this study could change current practice. Many patients with completely resected, early-stage sinonasal ACC might safely avoid postoperative radiation and its long-term side effects, improving their quality of life without compromising cancer control.",[25,26],[54,55,56,57,58,59,60,61],"Sinonasal Adenoid Cystic Carcinoma","Radiotherapy","Adjuvant","Watchful Waiting","Observational Study","Prospective Studies","Non-Inferiority Trials","Disease-Free Survival","NOT_YET_RECRUITING","2026-05-08",{"date":65,"type":33},"2026-05-12",{"date":67,"type":21},"2026-05-01",{"date":69,"type":21},"2032-05-01",{"name":39,"class":40},1,{"id":73,"slug":4,"hasResults":10,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":71},"100633145","NCT07522879","A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma","Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma: A Prospective, Multicenter Clinical Study","MRG003-SACC","Inclusion Criteria:\n\nAge ≥ 18 years, male or female. Histopathologically confirmed primary sinonasal adenoid cystic carcinoma (SNACC) that is locally recurrent after prior surgery and\u002For radiotherapy.\n\nEGFR expression positive by immunohistochemistry (IHC) performed at a central laboratory.\n\nMultidisciplinary team (MDT) assessment at baseline confirms that the tumor is not amenable to radical (R0) surgical resection.\n\nAt least one measurable lesion in the skull base\u002Fsinonasal region according to RECIST v1.1 (longest diameter ≥ 10 mm).\n\nEastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Adequate bone marrow, hepatic, renal, and cardiac function as defined by protocol-specified laboratory parameters.\n\nWilling to provide written informed consent (including consent for clinical treatment and biospecimen research) and able to comply with study procedures.\n\nExclusion Criteria:\n\nPrior treatment with any antibody-drug conjugate (ADC) that contains monomethyl auristatin E (MMAE) as the payload.\n\nPrior systemic chemotherapy containing epirubicin or any other anthracycline within 6 months before study enrollment.\n\nActive uncontrolled infection, or active autoimmune disease requiring systemic therapy.\n\nSymptomatic or urgent (e.g., requiring radiotherapy or surgery) central nervous system (CNS) metastases.\n\nKnown severe hypersensitivity to any component of the study drugs. Pregnant or breastfeeding women, or men\u002Fwomen planning to become pregnant within 6 months after the last dose of study treatment.\n\nAny medical or psychosocial condition that, in the investigator's judgment, may interfere with study participation, increase patient risk, or confound data interpretation.",{"count":80,"type":21},40,"INTERVENTIONAL",[83],"PHASE2","This prospective, multicenter clinical study aims to evaluate the efficacy and safety of neoadjuvant therapy with MRG003 (Becotatug vedotin) combined with epirubicin in patients with EGFR-positive, unresectable recurrent sinonasal adenoid cystic carcinoma (SNACC). The primary question is whether this combination can achieve a sufficient objective response rate (ORR) to enable subsequent radical surgery or improve disease control.",[25,26],[87,88,89,90,91,92,59],"EGFR protein","Unresectable","Adenoid cystic carcinoma","Sinonasal","Becotatug vedotin","Epirubicin",{"date":65,"type":33},{"date":67,"type":21},{"date":96,"type":21},"2030-07-01",{"name":39,"class":40},{"id":99,"slug":4,"hasResults":10,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":81,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":71},"100617583","NCT07320508","Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study","A Prospective, Multicenter Study of Transarterial Epirubicin Chemotherapy in the Treatment of Sinonasal Adenoid Cystic Carcinoma","EIC-SNACC","Inclusion Criteria:\n\n1. Age between 18 and 70 years.\n2. Histologically confirmed diagnosis of sinonasal adenoid cystic carcinoma (ACC).\n3. Tumor stage T3 or T4 according to the AJCC (American Joint Committee on Cancer) 8th edition staging system. Participants with lymph node metastasis must be amenable to surgical dissection. Those with distant metastasis must have stable disease.\n4. Ability to provide a sufficient volume (≥0.5 cm³) of fresh tumor tissue via biopsy or surgery for research purposes, with participant's informed consent.\n5. ECOG (Eastern Cooperative Oncology Group) performance status score of 0 to 2.\n6. Voluntary participation and provision of written informed consent. Good compliance, able to cooperate with treatment and follow-up.\n\nExclusion Criteria:\n\n1. Prior treatment with Epirubicin or any other anthracycline-based chemotherapy.\n2. Prior radiotherapy to the head and neck region.\n3. Administration of any other chemotherapy, targeted therapy, or immunotherapy within 4 weeks prior to study enrollment.\n4. Concurrent participation in another interventional drug clinical trial.\n5. Inadequate liver, kidney, or bone marrow function that does not meet the requirements for the planned treatment regimen.\n6. Contraindications to anthracycline-containing chemotherapy regimens: known allergy to anthracyclines, presence of ≥ Grade 2 peripheral neuropathy, or uncontrolled nausea\u002Fvomiting or chronic gastrointestinal diseases.\n7. Severe uncontrolled acute infection or decompensated major organ dysfunction.\n8. Pregnancy or lactation.","70 Years",{"count":107,"type":21},100,[83],"This study is for patients with locally advanced sinonasal adenoid cystic carcinoma (SNACC), a rare and challenging cancer that tends to invade nerves and the skull base. The research aims to test a new precise treatment strategy. First, all participants will receive three sessions of \"interventional chemotherapy\" (transarterial chemoembolization) with the drug Epirubicin, which delivers high-dose chemotherapy directly to the tumor to shrink it as much as possible. About 4-6 weeks after the third session, doctors will use MRI scans to evaluate how well the tumor responded. Based on this response, patients will follow one of two personalized treatment paths: those whose tumors did not completely disappear will undergo surgery followed by radiotherapy; those whose tumors show complete disappearance on imaging will receive precise radiotherapy alone, potentially avoiding major surgery. This is a prospective, multicenter study. The main goals are to evaluate the safety and effectiveness of this response-adapted strategy and to see if it can improve outcomes for patients with this difficult-to-treat cancer.",[25,26,92],[112,113,114],"transarterial chemoembolization","objective response rate","2-year progression-free surviva",{"date":65,"type":33},{"date":117,"type":33},"2026-01-20",{"date":119,"type":21},"2029-12-12",{"name":39,"class":40},{"id":122,"slug":4,"hasResults":10,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":10,"sex":16,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":71},"100420522","NCT04755855","Prospective Sinonasal Cancer Multi-institution Study","Sinonasal Cancer Study to Evaluate Oncologic Outcomes and Quality of Life","Inclusion Criteria:\n\n* Subjects between the ages of 30 days (non-inclusive) and 99 years (inclusive)\n* Patients with a diagnosis of sinonasal cancer\n* Patients undergoing treatment at Mayo Clinic\n\nExclusion Criteria:\n\n* Healthy individuals\n* Unwilling to sign the informed consent","30 Days","99 Years",{"count":50,"type":21},"This is a multi-institution prospective study of patients with sinonasal malignancies. The goal of this study is to learn more about the course of sinonasal cancer, treatment outcomes, and patient quality of life. In addition, central mutational and genomic analysis of tumor tissue will be evaluated.",[26],"2026-03-30",{"date":134,"type":33},"2026-04-03",{"date":136,"type":33},"2021-01-01",{"date":138,"type":21},"2031-01",{"name":140,"class":40},"Mayo Clinic",{"id":142,"slug":4,"hasResults":10,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":81,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100450906","NCT05151588","Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma","A Phase II Single-arm Study of Tazemetostat With Docetaxel, Cisplatin, and 5-fluorouracil as Preoperative Treatment for Locally Advanced Potentially Resectable SMARCB1 (INI-1)- Deficient Sinonasal Carcinoma","Inclusion Criteria:\n\n1. Males or females are \\>18 years of age with body weight ≥40kg at the time of providing voluntary written informed consent.\n2. Voluntarily sign the written informed consent and demonstrated willingness and ability to comply with all aspects of the protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF), and undergoing treatment and scheduled visits and examinations including follow up during the study period,\n3. Histologically and\u002For cytologically confirmed locally advanced (T3-T4bN0-N3M0) non-metastatic SMARCB1 (INI-1)-deficient sinonasal carcinoma\n4. For subjects who have experienced any clinically significant toxicity related to a prior anticancer treatment (i.e., chemotherapy, immunotherapy, and\u002For radiotherapy): at the time the subject provides voluntary written informed consent, all toxicities have either resolved to grade 1 per NCI CTCAE Version 5.0 OR are clinically stable and no longer clinically significant.\n5. Have measurable disease as defined by RECIST 1.1.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n7. Must have a life expectancy of at least 12 weeks before enrollment.\n8. Time between prior anticancer therapy and first dose of tazemetostat as follows:\n\n   Cytotoxic chemotherapy - At least 21 days Noncytotoxic chemotherapy (e.g., small molecule inhibitor) - At least 14 days. Nitrosoureas - At least 6 weeks. Monoclonal antibody - At least 28 days.\n9. Adequate haematological functions at baseline before commencement of study medication as defined below:\n\n   i. Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002Fliter without growth factor support (filgrastim or pegfilgrastim) for at least 14 days; and ii. Platelets ≥ 100 × 10\\^9\u002Fliter evaluated at least 7 days after platelet transfusion; and iii. Hemoglobin ≥ 9.0 x 10 \u002Flitre with blood transfusion allowed before study entry; and after treatment commencement\n10. Adequate liver function as defined at baseline before commencement of study medication below:\n\n    Total bilirubin ≤ 1.5 × the upper limit of normal (ULN) (except for unconjugated hyperbilirubinemia of Gilbert's syndrome) Alkaline phosphatase (ALP) (in the absence of bone disease), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN.\n11. Adequate renal function as defined below:\n\n    Creatinine \\\u003C 2.0 or calculated creatinine clearance ≥ 35 mL\u002Fminute per the Cockcroft and Gault formula\n12. For women of childbearing potential, a negative serum or urine pregnancy test within 14 days prior to the start of treatment. Women will be considered postmenopausal if they are amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n    i.) Women \\\u003C 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). ii.) Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n13. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and partner) to use a highly effective form(s) of contraception that results in a low failure rate (\\\u003C1% per year) when used consistently and correctly, starting during the screening period, continuing throughout the entire program period, and six months for female and at least three months for male patients after taking the last dose of tazemetostat.\n\nExclusion Criteria:\n\n1. Pre-existing or co-existing epithelioid sarcoma.\n2. Has a prior history of T-Cell lymphoblastic lymphoma, T-cell acute lymphoblastic leukemia, myelodysplastic syndrome, acute myeloid leukemia, or myeloproliferative neoplasm.\n3. Have undergone a solid organ transplant.\n4. Prior malignancy in the past 5 years.\n5. Confirm pregnant or breastfeeding.\n6. Prior exposure to tazemetostat or other inhibitor(s) of EZH2.\n7. On investigational therapy within 21 days at time of recruitment.\n8. Uncontrolled central nervous system (CNS) metastases requiring steroids.\n9. On medications that are known potent CYP3A4 inducers\u002Finhibitors (including St. John's wort)\n10. Unwilling to exclude Seville oranges, grapefruit juice, and grapefruit from their diet.\n11. Had major surgery within 4 weeks before the first dose of study drug. Note: Minor surgery (e.g., minor biopsy of extracranial site, central venous catheter placement, shunt revision) is permitted within 1 week prior to enrollment.\n12. Unable to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, vomiting) that might impair the bioavailability of tazemetostat.\n13. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II (Appendix 3), uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug; or cardiac ventricular arrhythmia.\n14. Have an active infection requiring systemic therapy.\n15. Known hypersensitivity to any component of tazemetostat.\n16. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the subject's participation in this study OR interfere with their ability to receive study treatment or complete the study.",{"count":148,"type":21},30,[83],"SMARCB1-deficient sinonasal carcinoma is very locally advanced malignancy at diagnosis which often precluded upfront radical resection. The investigators are now proposing a phase II single-arm study on tazemetostat in combination with docetaxel, cisplatin and 5-FU (known as TPF regimen) as preoperative therapy for locally advanced non-metastatic SMARCB1 (INI-1)-deficient sinonasal carcinoma, followed by radical resection and\u002For post-operative radiation therapy (with or without concurrent chemotherapy), and tazemetostat for another 6 months. It is hypothesized that addition of tazemetostat will improve objective response rate, resectability rate, orbit preservation rate after surgery, and hopefully survival outcomes with manageable safety profiles.",[26],[153,154,155],"Induction therapy","Chemotherapy","Surgery","2023-02-26",{"date":158,"type":33},"2023-02-28",{"date":160,"type":21},"2023-09-01",{"date":162,"type":21},"2027-08-31",{"name":164,"class":40},"Dr. Victor H.F. Lee",""]